Form 6-K ProQR Therapeutics N.V. For: Sep 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
ProQR Therapeutics N.V. (PRQR) PT Raised to $21 at Chardan Capital Markets
September 5, 2018 2:42 PM EDTChardan Capital Markets analyst Keay Nakae raised the price target on ProQR Therapeutics N.V. (NASDAQ: PRQR) to $21.00 (from $9.00) while maintaining a Buy rating after the company reported positive interim data from its Phase 1/2 clinical trial of QR-110 in patients with Lebers Congenital Amaurosis 10 (LCA 10).
Nakae commented, "We maintain our BUY rating and are increasing our 12-month price target to $21.00: We continue to believe that ProQR has the potential to become a significant... More
